Enzyme Technology
-
{
- All
- News
-
Scientists Create One Kidney That Can Match Any Patient, No Matter The Blood Type
Scientists have developed a universal kidney transplant by converting a donor kidney to blood type O, enabling compatibility with any recipient.
-
Midcaps Q2 Results Preview - Likely To Be A Mixed Bag For Chemicals: Nirmal Bang
Galaxy Surfactants, Fine Organics and Navin Fluorine are the brokerage Buy ideas in chemicals coverage.
-
Midcaps Q2 Results Preview - Likely To Be A Mixed Bag For Chemicals: Nirmal Bang
Galaxy Surfactants, Fine Organics and Navin Fluorine are the brokerage Buy ideas in chemicals coverage.
-
Advanced Enzyme Q1 Results Review - Growth Driven By Overseas Markets: Nirmal Bang
Since the company's largest product, Sera is expected to grow in mid-single digits, the rest of the human nutrition portfolio needs to do the heavy lifting, says the brokerage.
-
Advanced Enzyme Q1 Results Review - Growth Driven By Overseas Markets: Nirmal Bang
Since the company's largest product, Sera is expected to grow in mid-single digits, the rest of the human nutrition portfolio needs to do the heavy lifting, says the brokerage.
-
Advanced Enzyme Gains As Its COVID Fatigue Treatment Clears Clinical Trials
Advanced Enzyme conducted clinical trials on 200 patients suffering from post COVID fatigue symptoms.
-
Specialty Chemicals Check - Space Is Looking Selectively Special: Nirmal Bang
Global demand remains weak; India is an outlier.
-
Advanced Enzyme Q1 Review - Inline; Revenue Growth Was Driven Mainly By Human Nutrition Segment: Nirmal Bang
A meaningful acquisition(s) and/or strengthening of the leadership team could be some of the re-rating triggers.
-
Mid Cap Sector Q4 Results Preview — Another Quarter Of Mixed Performance For Specialty Chemicals: Nirmal Bang
Specialty chemicals coverage is expected to witness a muted quarter amid uncertain external environment.
-
Stock Market Today: Sensex, Nifty Snap Two-Day Gains; FPIs Remain Net Sellers
The S&P BSE Sensex was down 637 points or 1.04% at 60,657.45, while the NSE Nifty 50 was 190 points or 1.04% lower at 18,042.95.
-
Advanced Enzymes Q2 Results Reviews - Challenging Times: Nirmal Bang
The company's margin pressure continued on account of inflation-led pressure on raw materials and power and fuel cost.
-
Advanced Enzymes Q2 Results Reviews - Challenging Times: Nirmal Bang
The company's margin pressure continued on account of inflation-led pressure on raw materials and power and fuel cost.
-
Advanced Enzyme Q1 Review - Still Away From Normalcy: Nirmal Bang
Advanced Enzyme Q1 Review - Still Away From Normalcy: Nirmal Bang
-
Midcap Sector Q1 Preview- Demand Pressure For Select Chemical Players Besides Margin Contraction: Nirmal Bang
Midcap Sector Q1 Earnings Preview- Demand Pressure For Select Chemical Players Besides Margin Contraction: Nirmal Bang
-
Advanced Enzyme Q4 Review - Outlook Remains Challenging In Medium Term: ICICI Direct
Advanced Enzyme Q4 Review - Outlook Remains Challenging In Medium Term: ICICI Direct
-
Scientists Create One Kidney That Can Match Any Patient, No Matter The Blood Type
Scientists have developed a universal kidney transplant by converting a donor kidney to blood type O, enabling compatibility with any recipient.
-
Midcaps Q2 Results Preview - Likely To Be A Mixed Bag For Chemicals: Nirmal Bang
Galaxy Surfactants, Fine Organics and Navin Fluorine are the brokerage Buy ideas in chemicals coverage.
-
Midcaps Q2 Results Preview - Likely To Be A Mixed Bag For Chemicals: Nirmal Bang
Galaxy Surfactants, Fine Organics and Navin Fluorine are the brokerage Buy ideas in chemicals coverage.
-
Advanced Enzyme Q1 Results Review - Growth Driven By Overseas Markets: Nirmal Bang
Since the company's largest product, Sera is expected to grow in mid-single digits, the rest of the human nutrition portfolio needs to do the heavy lifting, says the brokerage.
-
Advanced Enzyme Q1 Results Review - Growth Driven By Overseas Markets: Nirmal Bang
Since the company's largest product, Sera is expected to grow in mid-single digits, the rest of the human nutrition portfolio needs to do the heavy lifting, says the brokerage.
-
Advanced Enzyme Gains As Its COVID Fatigue Treatment Clears Clinical Trials
Advanced Enzyme conducted clinical trials on 200 patients suffering from post COVID fatigue symptoms.
-
Specialty Chemicals Check - Space Is Looking Selectively Special: Nirmal Bang
Global demand remains weak; India is an outlier.
-
Advanced Enzyme Q1 Review - Inline; Revenue Growth Was Driven Mainly By Human Nutrition Segment: Nirmal Bang
A meaningful acquisition(s) and/or strengthening of the leadership team could be some of the re-rating triggers.
-
Mid Cap Sector Q4 Results Preview — Another Quarter Of Mixed Performance For Specialty Chemicals: Nirmal Bang
Specialty chemicals coverage is expected to witness a muted quarter amid uncertain external environment.
-
Stock Market Today: Sensex, Nifty Snap Two-Day Gains; FPIs Remain Net Sellers
The S&P BSE Sensex was down 637 points or 1.04% at 60,657.45, while the NSE Nifty 50 was 190 points or 1.04% lower at 18,042.95.
-
Advanced Enzymes Q2 Results Reviews - Challenging Times: Nirmal Bang
The company's margin pressure continued on account of inflation-led pressure on raw materials and power and fuel cost.
-
Advanced Enzymes Q2 Results Reviews - Challenging Times: Nirmal Bang
The company's margin pressure continued on account of inflation-led pressure on raw materials and power and fuel cost.
-
Advanced Enzyme Q1 Review - Still Away From Normalcy: Nirmal Bang
Advanced Enzyme Q1 Review - Still Away From Normalcy: Nirmal Bang
-
Midcap Sector Q1 Preview- Demand Pressure For Select Chemical Players Besides Margin Contraction: Nirmal Bang
Midcap Sector Q1 Earnings Preview- Demand Pressure For Select Chemical Players Besides Margin Contraction: Nirmal Bang
-
Advanced Enzyme Q4 Review - Outlook Remains Challenging In Medium Term: ICICI Direct
Advanced Enzyme Q4 Review - Outlook Remains Challenging In Medium Term: ICICI Direct
